VolitionRX Limited (VNRX)
Stock Price:
$3.04 USD
-0.22 (-6.75%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
145.68M |
| Revenue (ttm) |
22,834 |
| Net Income (ttm) |
-18.63M |
| Shares Out |
47.92M |
| EPS (ttm) |
-0.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$3.04 |
| Previous Close |
$3.26 |
| Change ($) |
-0.22 |
| Change (%) |
-6.75% |
| Day's Open |
3.16 |
| Day's Range |
3.02 - 3.24 |
| Day's Volume |
206,369 |
| 52-Week Range |
2.22 - 6.12 |
More Stats
| Market Cap |
145.68M |
| Enterprise Value |
127.86M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.92M |
| Float |
29.72M |
| EPS (basic) |
-0.44 |
| EPS (diluted) |
-0.45 |
| FCF / Share |
-0.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.33M |
| Short Ratio |
8.07 |
| Short % of Float |
4.48% |
| Beta |
1.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6,379.87 |
| PB Ratio |
8.31 |
| Revenue |
22,834 |
| Operating Income |
-18.99M |
| Net Income |
-18.63M |
| Free Cash Flow |
-16.42M |
| Net Cash |
17.82M |
| Net Cash / Share |
0.37 |
| Gross Margin |
74.87% |
| Operating Margin |
-83,145.34% |
| Profit Margin |
-81,567.80% |
| FCF Margin |
-71,900.09% |
| ROA |
-48.31% |
| ROE |
-106.38% |
| ROIC |
-504.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.14*
(134.87% upside)
Low
6.00
Current: $3.04
High
8.00
Target: 7.14
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.02 | - | - | - | - | - | - | 0.05 | - | - |
| Gross Profit | 0.02 | - | - | - | - | - | - | 0.05 | - | - |
| Operating Income | -16.04 | -17.90 | -14.70 | -12.43 | -10.01 | -5.95 | -4.58 | -4.08 | -2.61 | -0.01 |
| Net Income | -16.10 | -18.01 | -14.77 | -11.91 | -9.53 | -8.21 | -3.71 | -4.08 | -2.61 | -0.01 |
| Shares Outstanding | 39.18 | 31.39 | 26.39 | 23.05 | 17.73 | 13.44 | 10.83 | 9.36 | 5.77 | 2.29 |
| Earnings Per Share | -0.41 | -0.57 | -0.56 | -0.52 | -0.54 | -0.61 | -0.34 | -0.44 | -0.45 | -0.01 |
| Operating Cash Flow | -12.74 | -14.73 | -12.19 | -8.86 | -8.55 | -4.14 | -3.08 | -2.31 | -1.65 | - |
| Capital Expenditures | -0.51 | -0.30 | -1.43 | -0.42 | -0.08 | -0.30 | - | -0.09 | -0.03 | - |
| Free Cash Flow | -13.25 | -15.03 | -13.62 | -9.28 | -8.62 | -4.44 | -3.08 | -2.41 | -1.69 | - |
| Cash & Equivalents | 16.97 | 13.43 | 10.12 | 21.68 | 5.92 | 2.14 | 0.89 | 0.38 | 0.35 | 0.00 |
| Total Debt | 3.94 | 3.27 | 2.77 | 1.47 | 0.38 | - | - | 0.05 | 0.16 | 0.02 |
| Net Cash / Debt | 13.03 | 10.16 | 7.35 | 20.21 | 5.53 | 2.14 | 0.89 | 0.32 | 0.19 | -0.02 |
| Assets | 21.29 | 17.49 | 14.62 | 24.73 | 7.71 | 3.43 | 2.07 | 2.22 | 2.25 | - |
| Liabilities | 7.09 | 5.35 | 4.67 | 3.56 | 1.67 | 3.06 | 1.39 | 1.38 | 1.16 | 0.11 |
| Book Value | 14.20 | 12.14 | 9.96 | 21.18 | 6.04 | 0.37 | 0.68 | 0.83 | 1.09 | -0.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
VolitionRX Limited |
| Country |
United States |
| Employees |
50 |
| CEO |
Cameron John Reynolds |
Stock Information
| Ticker Symbol |
VNRX |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NYSEAMERICAN: VNRX |
Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.